Posted by Michael Wonder on 23 Mar 2020
Hansoh Pharma’s Ameile (almonertinib) receives marketing authorisation in China for second-line treatment for patients with EGFR T790 mutation non-small cell lung cancer
19 March 2020 - Hansoh Pharmaceutical Group announced that the National Medical Products Administration has granted marketing authorisation for Ameile (almonertinib, previously also known as HS-10296) once daily tablets for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), who have progressed on or after other EGFR tyrosine kinase inhibitor (TKI) therapy.
Ameile is the second third generation EGFR TKI to be approved for metastatic NSCLC patients with EGFR T790M.
The approval of AMEILE provides a highly efficacious treatment option with favourable safety profile for advanced NSCLC patients.
